Amgen recently announced that David M. Reese, M.D., its long-serving executive vice president and Chief Technology Officer, ...

Amgen (NASDAQ:AMGN) today announced the retirement of David M. Reese, M.D., executive vice president and Chief Technology Officer, effective June 30, 2026.

Amgen doubles down in New Albany: expansion plus solar, CO2 refrigeration and EV chargers as it chases carbon neutrality.

Shares of Merck and Amgen are seeing declines Friday morning, dragging the Dow Jones Industrial Average into negative territory. The Dow was most recently trading 168 points, or 0.3%, lower, as shares ...

Biotech giant Amgen on April 22 announced the retirement of David Reese, executive vice president and chief technology officer, who has been with the Thousand Oaks-based company for 21 years. Reese, ...

US biotech major Amgen has announced the retirement of David Reese, executive vice president and chief technology officer, ...

Delve into the pipeline strategy of major biotech Amgen, which is increasingly diversifying its growth engines.

A former Amgen Inc. employee filed a proposed class action challenging the biotechnology company’s practice of charging ...

As construction of Amgen’s second building move forward, the global biotech leader is pushing toward carbon neutrality by ...

Amgen's Tepezza became the first drug approved by the FDA for thyroid eye disease (TED) in 2020, and the company is now looking to extend its role with a new, more patient-friendly formulation. The ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.71. New data from a mid-stage study of an Amgen obesity drug showed that it ...

View Amgen Inc. AMGN stock quote prices, financial information, real-time forecasts, and company news from CNN.